ATLANTA, GA – – (ACCESSWIRE – December 7, 2022) – – Holzer & Holzer, LLC informs investors that a class action lawsuit was filed against Veru Inc. (“Veru” or the “Company”) (NASDAQ: VERU). The lawsuit alleges Veru made materially false and misleading statements and/or failed to disclose material adverse facts about data from a Phase 3 clinical trail for the Company’s drug, sabizabulin, and about Veru’s interactions with the FDA. Specifically, Veru mislead shareholders to believe its Phase 3 data was sufficient to support an Emergency Use Authorization (“EUA”) and even a New Drug Application (“NDA”) without further studies.
If you bought shares of Veru between May 11, 2022 and November 9, 2022, and you suffered a significant loss on that investment, you are encouraged to discuss your legal rights by contacting Corey Holzer, Esq. at email@example.com or Joshua Karr, Esq. at firstname.lastname@example.org, by toll-free telephone at (888) 508-6832 or you may visit the firm’s website at https://holzerlaw.com/case/veru/ to learn more.
The deadline to ask the court to be appointed lead plaintiff in the case is February 6, 2023.
Lead Plaintiff Deadline Has Passed
February 6, 2023